TITLE 22.EXAMINING BOARDS

Part 9. TEXAS STATE BOARD OF MEDICAL EXAMINERS

Chapter 182. USE OF EXPERTS

22 TAC §182.7

The Texas State Board of Medical Examiners proposes new §182.7, Interim Appointment, regarding the use of Executive Committee members to make interim appointments of expert panelists until the next board meeting.

During the two-month interval between meetings of the Medical Board, expert panelists with specialty qualifications may be needed as part of a case investigation. Interim appointments to the Expert Panel by a member of the Executive Committee and follow-up ratification by the Medical Board will prevent cases from going beyond the statutory investigatory timeline.

Michele Shackelford, General Counsel, Texas State Board of Medical Examiners, has determined that for the first five-year period the new section is in effect there will be no fiscal implications to state or local government as a result of enforcing the section as proposed. There will be no effect to individuals required to comply with the section as proposed.

Ms. Shackelford also has determined that for each year of the first five years the new section as proposed is in effect the public benefit anticipated as a result of enforcing the section will be to prevent cases from going beyond the statutory investigatory timeline. There will be no effect on small or micro businesses.

Comments on the proposal may be submitted to Colleen Klein, P.O. Box 2018, Austin, Texas 78768-2018. A public hearing will be held at a later date.

The new rule is proposed under the authority of the Occupation Code Annotated, §153.001 and §154.056(e), which provide that the Texas State Board of Medical Examiners may adopt rules and bylaws as necessary to perform its duties, regulate the practice of medicine in this state and enforce the Medical Practice Act.

No other statutes, articles or codes are affected by this proposal.

§182.7.Interim Appointment.

A member of the Executive Committee may make an interim appointment of an expert panelist to serve the board until the expert panelist can be considered for appointment by the board at the next board meeting.

This agency hereby certifies that the proposal has been reviewed by legal counsel and found to be within the agency's legal authority to adopt.

Filed with the Office of the Secretary of State on February 18, 2005.

TRD-200500775

Donald W. Patrick, MD, JD

Executive Director

Texas State Board of Medical Examiners

Earliest possible date of adoption: April 3, 2005

For further information, please call: (512) 305-7016


Part 15. TEXAS STATE BOARD OF PHARMACY

Chapter 291. PHARMACIES

Subchapter A. ALL CLASSES OF PHARMACIES

22 TAC §291.20

The Texas State Board of Pharmacy proposes amendments to §291.20, concerning Remote Pharmacy Services. The amendments, if adopted, will implement changes to §562.108 of the Texas Pharmacy Act made during the 78th Legislative session which allow Class E (non-resident) pharmacies located not more than 20 miles from an institution in this state that is licensed under Chapter 242 or 252, Health and Safety Code, to maintain controlled substances and dangerous drugs in an emergency medication kit used at an institution licensed under those chapters; and allow a United States Department of Veterans Affairs pharmacy or other federally operated pharmacy to maintain controlled substances and dangerous drugs in an emergency medication kit used at an institution that is licensed under Chapter 242, Health and Safety Code, and is a veterans home, as defined by §164.002, Natural Resources Code. The amendments, if adopted, also clarify inventory requirements for remote pharmacy services using automated pharmacy systems and remote pharmacy services using emergency medication kits; and update citations.

Gay Dodson, R.Ph., Executive Director/Secretary, has determined that, for the first five-year period the rule is in effect, there will be no fiscal implications for state or local government as a result of enforcing or administering the rule.

Ms. Dodson has determined that, for each year of the first five-year period the rule will be in effect, the public benefit anticipated as a result of enforcing the rule will be to increase the provision of pharmacy services within certain facilities and will clarify the inventory requirements to be consistent in remote pharmacy services .

There is no fiscal impact for small or large businesses or to other entities who are required to comply with this section.

Comments on the proposed amendments may be submitted to Allison Benz, R.Ph., M.S., Director of Professional Services, Texas State Board of Pharmacy, 333 Guadalupe Street, Suite 3-600, Austin, Texas, 78701, FAX (512) 305-8082. Comments must be received by 5 p.m., April 30, 2005.

The amendments are proposed under §§551.002, 554.051, 562.108, 562.109, and 562.110 of the Texas Pharmacy Act (Chapters 551 - 566 and 568 - 569, Texas Occupations Code). The Board interprets §551.002 as authorizing the agency to protect the public through the effective control and regulation of the practice of pharmacy. The Board interprets §554.051(a) as authorizing the agency to adopt rules for the proper administration and enforcement of the Act. The Board interprets §562.108 as authorizing the agency to adopt rules regarding emergency medication kits. The Board interprets §562.109 as authorizing the agency to adopt rules regarding automated pharmacy systems. The Board interprets §562.110 as authorizing the agency to adopt rules regarding telepharmacy systems.

The statutes affected by this rule: Texas Pharmacy Act, Chapters 551 - 566 and 568 - 569, Texas Occupations Code.

§291.20.Remote Pharmacy Services.

(a) Remote pharmacy services using automated pharmacy systems.

(1) Purpose. The purpose of this section is to provide standards for the provision of pharmacy services by a Class A or Class C pharmacy in a facility that is not at the same location as the Class A or Class C pharmacy through an automated pharmacy system as outlined in §562.109 of the Texas Pharmacy Act (Chapters 551 - 566 and 568 - 569, Occupations Code, as amended).

(2) - (4) (No change.)

(5) Records.

(A) - (E) (No change.)

(F) Inventory.

(i) A provider pharmacy shall:

(I) (No change.)

(II) keep a perpetual inventory of controlled substances and other drugs required to be inventoried under §291.17 of this title, that are received and dispensed or distributed from each remote site.

(ii) (No change.)

(b) Remote pharmacy services using emergency medication kits.

(1) Purpose. The purpose of this section is to provide standards for the provision of pharmacy services by a Class A or Class C pharmacy in a facility that is not at the same location as the Class A or Class C pharmacy through an emergency medication kit as outlined in §562.108 of the Texas Pharmacy Act (Chapters 551 - 566 and 568 - 569 , Occupations Code, as amended).

(2) Definitions. The following words and terms, when used in this section, shall have the following meanings, unless the context clearly indicates otherwise. All other words and terms shall have the meanings defined in §291.31 of this title.

(A) - (B) (No change.)

(C) Emergency medication kits--controlled substances and dangerous drugs maintained by a community pharmacy (Class A) , [ or ] an institutional pharmacy (Class C) at an institution licensed under Chapter 242 or 252, Health and Safety Code, a non-resident (Class E) pharmacy located not more than 20 miles from an institution licensed under Chapter 242 or 252, Health and Safety Code, or a United States Department of Veterans Affairs pharmacy or another federally operated pharmacy at an institution that is licensed under Chapter 242, Health and Safety Code, and is a veterans home, as defined by §164.002, Natural Resources Code, to meet the emergency medication needs of a resident at that institution.

(D) Remote site--a facility not located at the same location as a Class A , [ or ] Class C , Class E pharmacy or a United States Department of Affairs pharmacy or another federally operated pharmacy, at which remote pharmacy services are provided using an emergency medication kit.

(E) (No change.)

(F) Provider pharmacy--the community pharmacy (Class A) , [ or ] the institutional pharmacy (Class C) , the non-resident (Class E) pharmacy located not more than 20 miles from an institution licensed under Chapter 242 or 252, Health and Safety Code, or the United States Department of Veterans Affairs pharmacy or another federally operated pharmacy providing remote pharmacy services.

(G) (No change.)

(3) General requirements.

(A) - (C) (No change.)

(D) A provider pharmacy which is licensed as an institutional (Class C) or a non-resident (Class E) pharmacy is required to comply with the provisions of §§291.31 - 291.34 of this title and this section.

(E) (No change.)

(4) Operational standards.

(A) Application for permission to provide pharmacy services using an emergency medication kit.

(i) A Class A , [ or ] Class C , or Class E Pharmacy shall make application to the board to provide remote pharmacy services using an emergency medication kit. The application shall contain an affidavit with the notarized signatures of the pharmacist-in-charge, and the medical director or the person responsible for the on-site operation of the facility (e.g., administrator, owner, chief executive officer, chief operating officer), and include the following:

(I) - (II) (No change.)

(III) a statement indicating that the provider pharmacy and the healthcare facility have entered into a written contract or agreement which outlines the services to be provided and the responsibilities and accountabilities of each party in fulfilling the terms of the contract or agreement in compliance with federal and state laws and regulations; [ and ]

(IV) documentation that the emergency medication kit is located in a facility regulated under Chapter 242, or 252, Health and Safety Code ; and [ . ]

(V) documentation that the emergency kit is located in a facility that is not more than 20 miles from the Class E pharmacy providing the emergency kit.

(ii) - (iii) (No change.)

(B) - (G) (No change.)

(5) Records.

(A) - (D) (No change.)

(E) Inventory.

(i) A provider pharmacy shall:

(I) (No change.)

(II) keep a perpetual inventory of controlled substances and other drugs required to be inventoried under §291.17 of this title, that are received and dispensed or distributed from each remote site.

(ii) (No change.)

(c) Remote pharmacy services using telepharmacy systems.

(1) Purpose. The purpose of this section is to provide standards for the provision of pharmacy services by a Class A or Class C pharmacy in a healthcare facility that is not at the same location as a Class A or Class C pharmacy through a telepharmacy system as outlined in §562.110 of the Texas Pharmacy Act, Chapter 551 - 566 and 568 - 569 , Occupations Code.

(2) - (5) (No change.)

(d) (No change.)

This agency hereby certifies that the proposal has been reviewed by legal counsel and found to be within the agency's legal authority to adopt.

Filed with the Office of the Secretary of State on February 18, 2005.

TRD-200500756

Gay Dodson, R.Ph.

Executive Director/Secretary

Texas State Board of Pharmacy

Earliest possible date of adoption: April 3, 2005

For further information, please call: (512) 305-8028


Subchapter B. COMMUNITY PHARMACY (CLASS A)

22 TAC §291.33

The Texas State Board of Pharmacy proposes amendments to §291.33, concerning Operational Standards. The amendments, if adopted, will implement a portion of the recommendations of the Task Force on Patient Counseling requiring a pharmacist to ensure that the patient or patient's agent is offered information about refill prescriptions and requiring pharmacies to post notification in the pharmacy that a pharmacist is available to answer questions about prescription medications. In addition, the amendments, regarding generic substitution if adopted, will make changes to conform with proposed changes in §309.7 published elsewhere in this issue of the Texas Register .

Gay Dodson, R.Ph., Executive Director/Secretary, has determined that, for the first five-year period the rule is in effect, there may be financial savings to state and local governments. The LBB report estimates that allowing generic substitution of products not listed in the Orange Book would reduce the state's expenditure for prescription drugs for Medicaid by at least $9.9 million in All Funds for the 2006-2007 biennium. According to the LBB report, approximately $3.9 million of this amount could be saved for the General Revenue Fund.

Ms. Dodson has determined that, for each year of the first five-year period the rule will be in effect, the public benefit anticipated as a result of enforcing the rule will be requiring pharmacists to ensure that the patient or patient's agent is offered information about refill prescriptions and patient's are made aware of the availability of a pharmacist to answer questions about prescription medications. In addition, the public benefit anticipated as a result of enforcing the rule will be allowing the substitution of products not listed in the Orange Book saving patients and the State of Texas money.

There is no fiscal impact for small or large businesses or to other entities who are required to comply with this section.

Comments on the proposed amendments may be submitted to Allison Benz, R.Ph., M.S., Director of Professional Services, Texas State Board of Pharmacy, 333 Guadalupe Street, Suite 3-600, Austin, Texas, 78701, FAX (512) 305-8082. Comments must be received by 5 p.m., April 30, 2005.

The amendments are proposed under §551.002 and §554.051 of the Texas Pharmacy Act (Chapters 551 - 566 and 568 - 569, Texas Occupations Code). The Board interprets §551.002 as authorizing the agency to protect the public through the effective control and regulation of the practice of pharmacy. The Board interprets §554.051(a) as authorizing the agency to adopt rules for the proper administration and enforcement of the Act.

The statutes affected by this rule: Texas Pharmacy Act, Chapters 551 - 566 and 568 - 569, Texas Occupations Code.

§291.33.Operational Standards.

(a) - (b) (No change.)

(c) Prescription dispensing and delivery.

(1) Patient counseling and provision of drug information.

(A) (No change.)

(B) Such communication:

(i) shall be provided with each new prescription drug order[ , once yearly on maintenance medications, and if the pharmacist deems appropriate, with prescription drug order refills. (For the purposes of this clause, maintenance medications are defined as any medication the patient has taken for one year or longer) ];

(ii) - (iv) (No change.)

(C) - (D) (No change.)

(E) In addition to the requirements of subparagraphs (A) - (D) of this paragraph, if a prescription drug order is delivered to the patient at the pharmacy, the following is applicable.

(i) So that a patient will have access to information concerning his or her prescription, a prescription may not be delivered to a patient unless a pharmacist is in the pharmacy, except as provided in subsection (b) (3) [ (4) ] of this section or clause (ii) of this subparagraph.

(ii) - (iv) (No change.)

(F) (No change.)

(G) Except as specified in subparagraph (B) of this paragraph, in the best interest of the public health and to optimize drug therapy, upon delivery of a refill prescription, a pharmacist shall ensure that the patient or patient's agent is offered information about the refilled prescription. Either a pharmacist or other pharmacy personnel shall inform the patient or patient's agent that a pharmacist is available to discuss the patient's prescription and provide information.

(H) A pharmacy shall post a sign no smaller than 8.5 inches by 11 inches in clear public view at all locations in the pharmacy where a patient may pick up prescriptions. The sign shall contain the following statement in a font that is easily readable: "Do you have questions about your prescription? Ask the pharmacist." Such notification shall be in both English and Spanish.

(I) [ (G) ] The provisions of this paragraph do not apply to patients in facilities where drugs are administered to patients by a person required to do so by the laws of the state (i.e., nursing homes).

(2) (No change.)

(3) Generic Substitution.

(A) - (C) (No change.)

(D) Refills.

(i) (No change.)

(ii) Narrow therapeutic index drugs.

(I) The board, in consultation with the Texas State Board of Medical Examiners, has determined that no drugs shall be included on a list of narrow therapeutic index drugs as defined in §562.013, Occupations Code. [ The board has specified in §309.7 of this title (relating to dispensing responsibilities) that pharmacist shall use as a basis for determining generic equivalency, Approved Drug Products with Therapeutic Equivalence Evaluations and current supplements published by the Federal Food and Drug Administration, within the limitations stipulated in that publication. ]

(-a-) The board has specified in §309.7 of this title (relating to dispensing responsibilities) that for drugs listed in the publication, pharmacists shall use as a basis for determining gerenic equivalency, Approved Drug Products with Therapeutic Equivalence Evaluations and current supplements published by the Federal Food and Drug Administration, within the limitations stipulated in that publication. Pharmacists may only substitute products that are rated therapeutically equivalent in the Approved Drug Products with Therapeutic Equivalence Evaluations and current supplements.

(-b-) (No change.)

(II) (No change.)

(4) - (7) (No change.)

(d) - (i) (No change.)

This agency hereby certifies that the proposal has been reviewed by legal counsel and found to be within the agency's legal authority to adopt.

Filed with the Office of the Secretary of State on February 18, 2005.

TRD-200500757

Gay Dodson, R.Ph.

Executive Director/Secretary

Texas State Board of Pharmacy

Earliest possible date of adoption: April 3, 2005

For further information, please call: (512) 305-8028


Subchapter F. NON-RESIDENT PHARMACY (CLASS E)

22 TAC §291.104

The Texas State Board of Pharmacy proposes amendments to §291.104, concerning Generic Substitution. The amendments, if adopted, will make changes to conform with proposed changes in §309.7 published elsewhere in this issue of the Texas Register .

Gay Dodson, R.Ph., Executive Director/Secretary, has determined that, for the first five-year period the rule is in effect, there may be financial savings to state and local governments. The LBB report estimates that allowing generic substitution of products not listed in the Orange Book would reduce the state's expenditure for prescription drugs for Medicaid by at least $9.9 million in All Funds for the 2006-2007 biennium. According to the LBB report, approximately $3.9 million of this amount could be saved for the General Revenue Fund.

Ms. Dodson has determined that, for each year of the first five-year period the rule will be in effect, the public benefit anticipated as a result of enforcing the rule will be allowing the substitution of products not listed in the Orange Book saving patients and the State of Texas money.

There is no fiscal impact for small or large businesses or to other entities who are required to comply with this section.

Comments on the proposed amendments may be submitted to Allison Benz, R.Ph., M.S., Director of Professional Services, Texas State Board of Pharmacy, 333 Guadalupe Street, Suite 3-600, Austin, Texas, 78701, FAX (512) 305-8082. Comments must be received by 5 p.m., April 30, 2005.

The amendments are proposed under §551.002 and §554.051 of the Texas Pharmacy Act (Chapters 551 - 566 and 568 - 569, Texas Occupations Code). The Board interprets §551.002 as authorizing the agency to protect the public through the effective control and regulation of the practice of pharmacy. The Board interprets §554.051(a) as authorizing the agency to adopt rules for the proper administration and enforcement of the Act. Section 554.051(b) which authorizes the agency to make a rule concerning the operation of a licensed pharmacy located in this state applicable to a pharmacy licensed by the board that is located in another state, if the board determines the rule is necessary to protect the health and welfare of the citizens of this state.

The statutes affected by this rule: Texas Pharmacy Act, Chapters 551 - 566 and 568 - 569, Texas Occupations Code.

§291.104.Operational Standards.

(a) - (b) (No change.)

(c) Generic Substitution. Unless compliance would violate the pharmacy or drug laws or rules in the state in which the pharmacy is located:

(1) (No change.)

(2) Pharmacists shall use as a basis for the determination of generic equivalency as defined in the Subchapter A, Chapter 562 of the Act, the following [ provided the pharmacist uses as a basis for the determination of generic equivalency, the publication, Approved Drug Products With Therapeutic Equivalence Evaluations and current supplements published by the Federal Food and Drug Administration within the limitations stipulated in that publication ].

(A) For drugs listed in the publication, pharmacists shall use Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) and current supplements published by the Federal Food and Drug Administration, within the limitations stipulated in that publication, to determine generic equivalency. Pharmacists may only substitute products that are rated therapeutically equivalent in the Orange Book and have an "A" rating. "A" rated drug products include but are not limited to, those designated AA, AB, AN, AO, AP, or AT in the Orange Book.

(B) For drugs not listed in the Orange Book, pharmacists shall use their professional judgment to determine generic equivalency.

(d) - (f) (No change.)

This agency hereby certifies that the proposal has been reviewed by legal counsel and found to be within the agency's legal authority to adopt.

Filed with the Office of the Secretary of State on February 18, 2005.

TRD-200500759

Gay Dodson, R.Ph.

Executive Director/Secretary

Texas State Board of Pharmacy

Earliest possible date of adoption: April 3, 2005

For further information, please call: (512) 305-8028


Chapter 295. PHARMACISTS

22 TAC §295.13

The Texas State Board of Pharmacy proposes amendments to §295.13, concerning Drug Therapy Management by a Pharmacist under Written Protocol of a Physician. The amendments, if adopted, will delete the requirement for pharmacists participating in drug therapy management under the written protocol of a physician to notify the Board of participation.

Gay Dodson, R.Ph., Executive Director/Secretary, has determined that, for the first five-year period the rule is in effect, there will be no fiscal implications for state or local government as a result of enforcing or administering the rule.

Ms. Dodson has determined that, for each year of the first five-year period the rule will be in effect, the public benefit anticipated as a result of enforcing the rule will be to clarify the notification requirements for pharmacists participating in drug therapy management under the written protocol of a physician.

There is no fiscal impact for small or large businesses or to other entities who are required to comply with this section.

Comments on the proposed amendments may be submitted to Allison Benz, R.Ph., M.S., Director of Professional Services, Texas State Board of Pharmacy, 333 Guadalupe Street, Suite 3-600, Austin, Texas, 78701, FAX (512) 305-8082. Comments must be received by 5 p.m., April 30, 2005.

The amendments are proposed under §551.002 and §554.051 of the Texas Pharmacy Act (Chapters 551 - 566 and 568 - 569, Texas Occupations Code). The Board interprets §551.002 as authorizing the agency to protect the public through the effective control and regulation of the practice of pharmacy. The Board interprets §554.051(a) as authorizing the agency to adopt rules for the proper administration and enforcement of the Act. The Board interprets §554.051(c) as authorizing the agency to adopt rules regarding records to be maintained by a pharmacist performing a specific act under a written protocol.

The statutes affected by this rule: Texas Pharmacy Act, Chapters 551 - 566 and 568 - 569, Texas Occupations Code.

§295.13.Drug Therapy Management by a Pharmacist under Written Protocol of a Physician.

(a) (No change.)

(b) Definitions. The following words and terms, when used in this section, shall have the following meanings, unless the context clearly indicates otherwise.

(1) Act--The Texas Pharmacy Act, Chapter 551 - 566 and 568 - 569 , Occupations Code, as amended.

(2) - (6) (No change.)

(c) Pharmacist Training Requirements [ Notification ].

(1) Initial requirements. [ notification. Prior to initially engaging in drug therapy management, a ] A pharmacist shall maintain and provide to the Board within 24 hours of request [ provide the board with: ]

[ (A) the name, license number, and address of the supervising physician; ]

[ (B) the address where the records of such drug therapy management are maintained; and ]

[ (C) ] a statement attesting to the fact that the pharmacist has within the last year:

(A) [ (i) ] completed at least six hours of continuing education related to drug therapy offered by a provider approved by the Accreditation Council for Pharmacy Education [ American Council on Pharmaceutical Education ] (ACPE); or

(B) [ (ii) ] engaged in drug therapy management as allowed under previous laws or rules. A statement from the physician supervising the acts shall be sufficient documentation.

(2) Continuing requirements. A pharmacist engaged in drug therapy management shall [ : ]

[ (A) ] annually complete six hours of continuing education related to drug therapy offered by a provider approved by the Accreditation Council for Pharmacy Education [ American Council on Pharmaceutical Education ] (ACPE). (These hours may be applied towards the hours required for renewal of a license to practice pharmacy.)

[ (B) notify the board of any change in supervising physician or change in the address where the records of drug therapy management are maintained. ]

(d) - (g) (No change.)

This agency hereby certifies that the proposal has been reviewed by legal counsel and found to be within the agency's legal authority to adopt.

Filed with the Office of the Secretary of State on February 18, 2005.

TRD-200500758

Gay Dodson, R.Ph.

Executive Director/Secretary

Texas State Board of Pharmacy

Earliest possible date of adoption: April 3, 2005

For further information, please call: (512) 305-8028


Chapter 309. GENERIC SUBSTITUTION

22 TAC §§309.2, 309.3, 309.7

The Texas State Board of Pharmacy proposes amendments to §309.2, concerning Definitions, §309.3, concerning Generic Substitution and §309.7, concerning Dispensing Responsibilities. The amendments, if adopted, will implement recommendations made by the Legislative Budget Board Staff Performance Report to the 79th Legislature to allow the substitution of products not listed in the U.S. Food and Drug Administration's Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). In addition, the amendments to §309.2, if adopted, will correct definitions to conform with definitions in Chapter 291.

Gay Dodson, R.Ph., Executive Director/Secretary, has determined that, for the first five-year period the rules are in effect, there may be financial savings to state and local governments as follows:

Figure: 22 TAC Chapter 309--Preamble

The LBB report estimates that allowing generic substitution of products not listed in the Orange Book would reduce the state's expenditure for prescription drugs for Medicaid by at least $9.9 million in All Funds for the 2006-2007 biennium. According to the LBB report, approximately $3.9 million of this amount could be saved for the General Revenue Fund.

Ms. Dodson has determined that, for each year of the first five-year period the rules will be in effect, the public benefit anticipated as a result of enforcing the rules will be allowing the substitution of products not listed in the Orange Book saving patients and the State of Texas money.

There is no fiscal impact for small or large businesses or to other entities who are required to comply with the sections.

Comments on the proposed amendments may be submitted to Allison Benz, R.Ph., M.S., Director of Professional Services, Texas State Board of Pharmacy, 333 Guadalupe Street, Suite 3-600, Austin, Texas, 78701, FAX (512) 305-8082. Comments must be received by 5 p.m., April 30, 2005.

The amendments are proposed under §551.002 and §554.051 of the Texas Pharmacy Act (Chapters 551 - 566 and 568 - 569, Texas Occupations Code). The Board interprets §551.002 as authorizing the agency to protect the public through the effective control and regulation of the practice of pharmacy. The Board interprets §554.051(a) as authorizing the agency to adopt rules for the proper administration and enforcement of the Act.

The statutes affected by this rule: Texas Pharmacy Act, Chapters 551 - 566 and 568 - 569, Texas Occupations Code.

§309.2.Definitions.

The following words and terms, when used in this chapter, shall have the following meanings, unless the context clearly indicates otherwise. Any term not defined in this section shall have the definition set out in the Act, §551.003 and Chapter 562.

(1) Act--The Texas Pharmacy Act, Occupations Code, Subtitle J, as amended.

(2) Data communication device--An electronic device that receives electronic information from one source and transmits or routes it to another (e.g., bridge, router, switch, or gateway).

(3) Electronic prescription drug order--A prescription drug order which is transmitted by an electronic device to the receiver (pharmacy). [ Electronic prescription drug order includes computer to computer transmission, but does not include facsimile prescription drug orders. ]

[ (4) Facsimile prescription drug order--A prescription drug order which is transmitted by an electronic device which sends an exact image to the receiver (pharmacy).]

(4) [ (5) ] Generically equivalent--A drug that is pharmaceutically equivalent and therapeutically equivalent to the drug prescribed.

(5) [ (6) ] Pharmaceutically equivalent--Drug products that have identical amounts of the same active chemical ingredients in the same dosage form and that meet the identical compendial or other applicable standards of strength, quality, and purity according to the United States Pharmacopoeia or another nationally recognized compendium.

(6) [ (7) ] Therapeutically equivalent--Pharmaceutically equivalent drug products that, if administered in the same amounts, will provide the same therapeutic effect, identical in duration and intensity.

(7) [ (8) ] Original prescription--The:

(A) original written prescription drug orders; or

(B) original verbal or electronic prescription drug orders reduced to writing either manually or electronically by the pharmacist.

(8) [ (9) ] Practitioner--

(A) A person licensed or registered to prescribe, distribute, administer, or dispense a prescription drug or device in the course of professional practice in this state, including a physician, dentist, podiatrist, therapeutic optometrist, or veterinarian but excluding a person licensed under this subtitle;

(B) A person licensed by another state, Canada, or the United Mexican States in a health field in which, under the law of this state, a license holder in this state may legally prescribe a dangerous drug;

(C) A person practicing in another state and licensed by another state as a physician, dentist, veterinarian, or podiatrist, who has a current federal Drug Enforcement Administration registration number and who may legally prescribe a Schedule II, III, IV, or V controlled substance, as specified under Chapter 481, Health and Safety Code, in that other state; or

(D) An advanced practice nurse or physician assistant to whom a physician has delegated the authority to carry out or sign prescription drug orders under §§157.052, 157.053, 157.054, 157.0541, or 157.0542, Occupations Code.

§309.3.Generic Substitution.

(a) - (d) (No change.)

(e) Refills.

(1) (No change.)

(2) Narrow therapeutic index drugs.

(A) The board, in consultation with the Texas State Board of Medical Examiners, has determined that no drugs shall be included on a list of narrow therapeutic index drugs as defined in §562.013, Occupations Code. [ The board has specified in §309.7 of this title (relating to dispensing responsibilities) that pharmacist shall use as a basis for determining generic equivalency, Approved Drug Products with Therapeutic Equivalence Evaluations and current supplements published by the Federal Food and Drug Administration, within the limitations stipulated in that publication. ]

(i) The board has specified in §309.7 of this title (relating to dispensing responsibilities) that for drugs listed in the publication, pharmacist shall use as a basis for determining generic equivalency, Approved Drug Products with Therapeutic Equivalence Evaluations and current supplements published by the Federal Food and Drug Administration, within the limitations stipulated in that publication. For drugs listed in the publications, pharmacists [ Pharmacists ] may only substitute products that are rated therapeutically equivalent in the Approved Drug Products with Therapeutic Equivalence Evaluations and current supplements.

(ii) (No change.)

(B) (No change.)

§309.7.Dispensing Responsibilities.

(a) The determination of the drug product to be substituted as authorized by the Subchapter A, Chapter 562 of the Act, is the professional responsibility of the pharmacist, and the pharmacist may not dispense any product that does not meet the requirements of the Subchapter A, Chapter 562 of the Act. As specified in Chapter 562 of the Act and §309.2 of this title (relating to definitions), a generically equivalent product is one that is pharmaceutically equivalent and therapeutically equivalent to the drug prescribed.

(b) Pharmacists shall use [ utilize ] as a basis for the determination of generic equivalency as defined in the Subchapter A, Chapter 562 of the Act, the following: [ Approved Drug Products With Therapeutic Equivalence Evaluations (Orange Book) and current supplements published by the Federal Food and Drug Administration, within the limitations stipulated in that publication. ]

(1) For drugs listed in the publication, pharmacists shall use Approved Drug Products With Therapeutic Equivalence Evaluations (Orange Book) and current supplements published by the Federal Food and Drug Administration, within the limitations stipulated in that publication, to determine generic equivalency. Pharmacists may only substitute products that are rated therapeutically equivalent in the Orange Book and have an "A" rating. "A" rated drug products include but are not limited to, those designated AA, AB, AN, AO, AP, or AT in the Orange Book.

(2) For drugs not listed in the Orange Book, pharmacists shall use their professional judgment to determine generic equivalency.

[ (c) Pharmacists may only substitute products that are rated therapeutically equivalent in the Orange Book and have an "A" rating. "A" rated drug products include but are not limited to, those designated AA, AB, AN, AO, AP, or AT in the Orange Book.]

This agency hereby certifies that the proposal has been reviewed by legal counsel and found to be within the agency's legal authority to adopt.

Filed with the Office of the Secretary of State on February 18, 2005.

TRD-200500760

Gay Dodson, R.Ph.

Executive Director/Secretary

Texas State Board of Pharmacy

Earliest possible date of adoption: April 3, 2005

For further information, please call: (512) 305-8028


Part 39. TEXAS BOARD OF PROFESSIONAL GEOSCIENTISTS

Chapter 851. TEXAS BOARD OF PROFESSIONAL GEOSCIENTISTS LICENSING RULES

Subchapter A. LICENSING

22 TAC §851.32

The Texas Board of Professional Geoscientists (TBPG) proposes 22, Texas Administrative Code Chapter 851, §851.32, concerning continuing education. This newly proposed rule establishes both requirements and procedures related to the continuing education of licensed geoscientists in the State of Texas. Legislation enactment in 2001 of Senate Bill 405 required the Texas Board of Professional Geoscientists to adopt and implement a recommended timeline and criteria by which continuing education rules would be established that would enable licensed geoscientists to renew their licenses. The proposed rule provides language clarifying the agency's requirement of number of educational hours as well as acceptable courses applicable to continuing education. The need for this clarification is based on feedback from the geological community in the agency's initial year of operation.

Michael D. Hess, Executive Director of the Texas Board of Professional Geoscientists, has determined that for the first five years that this rule is in effect there will be no fiscal implication for state and local government as a result of enforcement and administration of this section.

Mr. Hess has also determined that for each year of the first five years that this section is in effect, the State of Texas can anticipate public benefit as a result of enforcement and enhancement of the professional practice of geology through the requirement of an increased level of education for the geoscience licensed population. There will not be an effect on small or micro businesses, however it is anticipated that there will be an economic cost to licensees in order to take the required educational courses.

Comments on the proposal may be submitted in writing to Michael D. Hess, Executive Director, P.O. Box 13225, Austin, Texas 78701, (512) 936-4401. Comments may also be submitted electronically to geoscience@tbpg.state.tx.us or faxed to (512) 936-4409. All comments must be received 30 days after publication of this rule in the Texas Register . All requests for a public hearing on the proposed section submitted under the Administrative Procedure Act must be received by the Executive Director not more than 15 calendar days after notice of a proposed new section has been published in the Texas Register .

The new section is proposed under the Texas Occupations Code, Chapter 1002, which authorizes the Board to adopt a mandated continuing education process and criteria by which all licensees will participate prior to their annual license renewal.

The proposed section implements the Texas Occupations Code, §1002.302.

§851.32.Continuing Education Program.

(a) Each license holder shall meet the Continuing Education Program (CEP) requirements for professional development as a condition for license renewal.

(b) Terms used in this section are defined as follows:

(1) Professional Development Hour (PDH)--A contact hour (clock hour) of CEP activity. PDH is the basic unit for CEP reporting.

(2) Continuing Education Unit (CEU)--Unit of credit customarily used for continuing education courses. One continuing education unit equals 10 hours of class in an approved continuing education course.

(3) College/Unit Semester/Quarter Hour--Credit for course in a discipline of geoscience or other related technical elective of the discipline.

(4) Course/Activity--Any qualifying course or activity with a clear purpose and objective which will maintain, improve, or expand the skills and knowledge relevant to the license holder's field of practice.

(c) Every license holder is required to obtain 15 PDH units during the renewal period year.

(d) A minimum of 1 PDH per renewal period must be in the area of professional ethics, roles and responsibilities of professional geoscientists, or review on-line of the Texas Geoscientist Practice Act and Board Rules.

(e) If a license holder exceeds the annual requirement in any renewal period, a maximum of 30 PDH units may be carried forward into the subsequent renewal periods.

(f) PDH units may be earned as follows:

(1) Successful completion or auditing of college credit courses.

(2) Successful completion of continuing education courses, either offered by a professional or trade organization, university or college, or offered in-house by a corporation, other business entity, professional or technical societies, associations, agencies, or organizations, or other group.

(3) Successful completion of correspondence, on-line, televised, videotaped, and other short courses/tutorials.

(4) Presenting or attending qualifying seminars, in-house courses, workshops, or professional or technical presentations made at meetings, conventions, or conferences sponsored by a corporation, other business entity, professional or technical societies, associations, agencies, or organizations, or other group.

(5) Teaching or instructing as listed in paragraphs (1) - (4) of this section.

(6) Authoring published papers, articles, books, or accepted licensing examination items.

(7) Active participation in professional or technical societies, associations, agencies, or organizations, including:

(A) Serving as an elected or appointed official;

(B) Serving on a committee of the organization;

(C) Serving in other official positions.

(8) Patents Issued.

(9) Engaging in self-directed course work.

(10) Software Programs Published.

(g) All activities described in subsection (f) of this section shall be relevant to the practice of a discipline of geoscience and may include technical, ethical, or managerial content.

(h) The conversion of other units of credit to PDH units is as follows and subject to subsection (g) of this section

(1) 1 College or unit semester hour--15 PDH

(2) 1 College or unit quarter hour--10 PDH

(3) 1 Continuing Education Unit--10 PDH

(4) 1 Hour of professional development in course work, seminars, or professional or technical presentations made at meetings, conventions, or conferences--1 PDH

(5) 1 Hour of professional development through self-directed course study (Not to exceed 5 PDH)--1 PDH

(6) Each published paper or article--10 PDH and book--45 PDH

(7) Active participation, as defined in subsection (f)(7) of this section, in professional or technical society, association, agency, or organization (Not to exceed 5 PDH per year)--1 PDH

(8) Each patent issued--15 PDH

(9) Each software program published--15 PDH

(10) Teaching or instructing as described in subsection (f)(5) of this section--3 times the PDH credit earned.

(i) Determination of Credit

(1) The Board shall be the final authority with respect to whether a course or activity meets the requirements of these rules.

(2) The Board shall not pre-approve or endorse any CEP activities during the first two years after the effective date of this rule. It is the responsibility of each license holder to assure that all PDH credits claimed meet CEP requirements. However, a course provider may contact the Board for an opinion for whether or not a course or technical presentation would meet the CEP requirements. Two years after the effective date of this rule, pre-approval will be required.

(3) Credit for college or community college approved courses will be based upon course credit established by the college.

(4) Credit for qualifying seminars and workshops will be based on one PDH unit for each hour of attendance. Attendance at qualifying programs presented at professional and/or technical society meetings will earn PDH units for the actual time of each program.

(5) Credit for self-directed course work will be based on one PDH unit for each hour of study and is not to exceed 5 PDH per renewal period. Credit determination for self-directed course work is the responsibility of the license holder and subject to review as required by the board.

(6) Credit determination for activities described in subsection (h)(6) of this section is the responsibility of the license holder and subject to review as required by the board.

(7) Credit for activity described in subsection (h)(7) of this section requires that a license holder serve as an officer of the organization, actively participate in a committee of the organization, or perform other activities such as making or attending a presentation at a meeting or writing a paper presented at a meeting. PDH credits are not earned until the end of each year of service is completed.

(8) Teaching credit, as defined in subsection (f)(5) of this section, is valid for teaching a course or seminar for the first time only.

(j) The license holder is responsible for maintaining records to be used to support credits claimed. Records required include, but are not limited to:

(1) A log, on a form provided by TBPG, showing the type of activity claimed, sponsoring organization, location, duration, instructor's or speaker's name, and PDH credits earned; and

(2) Attendance verification records in the form of completion certificates, receipts, attendance roster, or other documents supporting evidence of attendance.

(k) The license holder must submit CEP certification on the log form provided by TBPG and a list of each activity, date, and hours claimed that satisfy the CEP requirement for that renewal year when audited. A percentage of the licenses will be randomly audited each year.

Figure: 22 TAC §851.32(k) (.pdf)

(l) CEP records for each license holder must be maintained for a period of three years by the license holder.

(m) CEP records for each license holder are subject to audit by the board or its authorized representative.

(1) Copies must be furnished, if requested, to the Board or its authorized representative for audit verification purposes.

(2) If upon auditing a license holder, the Board finds that the activities cited do not fall within the bounds of educational, technical, ethical, or professional management activities related to the practice of geoscience; the board may require the license holder to acquire additional PDH as needed to fulfill the minimum CEP requirements.

(n) A license holder may be exempt from the professional development educational requirements for one of the following reasons listed in paragraphs (1) - (5) of this subsection:

(1) New license holders by way of examination shall be exempt for their first renewal period.

(2) A license holder serving on active duty and deployed outside the United States, its possessions and territories, in or for the military service of the United States for a period of time exceeding one hundred twenty (120) consecutive days in a year shall be exempt from obtaining the professional development hours required during that year.

(3) A license holder employed outside the United States, its possessions and territories, actively engaged in the practice of geoscience for a period of time exceeding three hundred (300) consecutive days in a year shall be exempt from obtaining the professional development hours required during that year except for five (5) hours of self-directed course work.

(4) License holders who list their status as "Inactive" and who further certify that they are no longer receiving any remuneration from providing professional geoscience services in Texas shall be exempt from the professional development hours required.

(5) License holders experiencing long term physical disability or illness. may be exempt by applying for "inactive" status. Supporting documentation must be furnished to the board.

(o) A license holder may bring an inactive license to active status by obtaining all delinquent PDH units. However, if the total number required to become current exceeds 30 units, then 30 units shall be the maximum number required.

(p) Noncompliance:

(1) If a license holder does not certify that CEP requirements have been met for a renewal period, the license shall be considered expired and subject to late fees and penalties.

(2) A determination by audit that CEP requirements have been falsely reported shall be considered to be misconduct and will subject the license holder to disciplinary action.

This agency hereby certifies that the proposal has been reviewed by legal counsel and found to be within the agency's legal authority to adopt.

Filed with the Office of the Secretary of State on February 16, 2005.

TRD-200500738

Michael D. Hess

Executive Director

Texas Board of Professional Geoscientists

Earliest possible date of adoption: April 3, 2005

For further information, please call: (512) 936-4400